Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Zydus Lifesciences Limited Press Release Nov 06 2023

· Issued by Zydus Lifesciences Limited via NSE India

Filed with NSE · · 8 pages · English

Summary by 6ix AI

The approval is based on the company's New Drug Application for ZITUVIMET, which combines sitagliptin and metformin hydrochloride. This drug aims to improve glycemic control in adults and is compliant with current USFDA standards. The approval is expected to enhance accessibility and affordability of diabetes treatment options.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 06, 2023, titled "Zydus receives USFDA approval for ZITUVIMETTM to treat adult patients with type 2 diabetes mellitus".

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases